The use of selective estrogen receptor modulator (SERM), such as tamoxifen, is found to be a risk factor for adenomyosis in humans, and tamoxifen exposure also induces adenomyosis in mice [9,10]. This evidence concerns the gene ESR1 and adenomyosis.